MANE vs MDCX

Veradermics, Incorporated vs Medicus Pharma Ltd. — Valuation Comparison 2026

MANE

Pharmaceutical Preparations
Veradermics, Incorporated
Quality
5.0
out of 10
Value Trap
Price
$100.91
Last close
Models
10/13
Active
VS

MDCX

Pharmaceutical Preparations
Medicus Pharma Ltd.
Quality
3.2
out of 10
Value Trap
12
SAFE
Price
$0.38
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType MANE Fair ValueMANE Upside MDCX Fair ValueMDCX Upside
Bayesian DCF Intrinsic $33.12 -67.2% $0.11 -69.8%
Earnings Power Value Intrinsic $29.35 -56.7%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $7.73 -92.3% $0.21 -43.4%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for MANE vs MDCX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MANE vs MDCX — Which Stock Is More Undervalued?

MANE scores higher with a 5.0/10 quality rating vs MDCX's 3.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Veradermics, Incorporated (MANE) and Medicus Pharma Ltd. (MDCX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MANE currently trades at $100.91 with a QOC of 5.0/10, while MDCX trades at $0.38 with a QOC of 3.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).